Blueprint library/Recall

Product Recall & Market Action Management Software

Recalls and market actions. Find the exact population, reach every consignee, prove effectiveness.

Run health-hazard evaluation, affected-lot and unit scope, recall strategy, authority communication, consignee notification, response tracking, product reconciliation, effectiveness checks, status reporting, and termination.

Recall population propagation
Scope is versioned from genealogy, then reconciled through direct and onward distribution to effectiveness and termination.
A product recall propagating from health-hazard evaluation through lots, consignees, returns and effectiveness checks
Risk
Health hazard, uncertainty and classification establish the required action.
Scope v03
Three lots are included; one is excluded with filter and batch genealogy.
Field
Direct and onward consignee populations keep separate contact and product states.
Termination
Open units, contacts and failed checks remain explicit release gates.

A recall is a controlled response to product already beyond the manufacturer's direct control. Speed matters, but speed without correct scope creates two risks: failing to reach affected patients and removing unaffected product during a shortage.

Seal connects the initiating signal, health-hazard evaluation, product and defect, lots or serials, genealogy, distribution, consignees, inventory, recall strategy, regulatory communication, notifications, responses, effectiveness checks, returns, corrections, destruction, reconciliation, status reports, CAPA, and termination.

FDA's industry recall guidance hub brings together Part 7 guidance, notification, status, and effectiveness-check resources for drugs, devices, and other regulated products.

01

The initiating signal remains connected to the action

Complaint, adverse event, deviation, OOS, stability failure, supplier alert, data-integrity concern, inspection finding, counterfeit report, labeling error, device failure, or authority request can trigger assessment.

The original signal, evidence, detection date, awareness date, reporter, products, immediate containment, and preliminary scope remain permanent even as understanding changes.

02

Health-hazard evaluation frames urgency and depth

Defect, failure mode, exposure, severity, probability, detectability, vulnerable populations, clinical consequences, reversibility, existing controls, distributed quantity, uncertainty, and medical or technical assessment support risk classification.

Recall population propagation
Scope is versioned from genealogy, then reconciled through direct and onward distribution to effectiveness and termination.
A product recall propagating from health-hazard evaluation through lots, consignees, returns and effectiveness checks
Risk
Health hazard, uncertainty and classification establish the required action.
Scope v03
Three lots are included; one is excluded with filter and batch genealogy.
Field
Direct and onward consignee populations keep separate contact and product states.
Termination
Open units, contacts and failed checks remain explicit release gates.
Fig. 1 / The originating defect propagates through genealogy and distribution into a bounded consignee population, then returns through responses and reconciliation

The evaluation records evidence and dissent. Classification does not replace jurisdiction-specific authority decisions.

03

Scope begins broad enough to protect patients

Potentially affected product, lots, serials, batches, strengths, pack sizes, markets, date ranges, sites, lines, components, suppliers, equipment, software, labeling versions, and distribution channels form the initial population.

Scope expansion and narrowing retain evidence, rationale, approver, and time. A root cause discovered later does not rewrite the earlier containment decision.

04

Genealogy makes scope precise

Raw materials, components, bulk, intermediates, packaging orders, labels, serials, cases, pallets, samples, rework, returned product, and released inventory remain traversable forward and backward.

Friday 4pm: supplier calls about contamination
Lot 2024-0892
Contamination
reported
12 containers
3 in Freezer A
5 in Freezer B
4 consumed
4 batches
B-2024-038
B-2024-041
B-2024-044, 047
Impact
2 in quarantine
1 shipped (hold)
1 in testing
Without Seal
Dig through records all weekend
Maybe miss a batch
Recall scope unclear Monday
With Seal
Query: 30 seconds
Every container, every batch, every product
Recall scope defined before you leave
Fig. 2 / A quality signal can trace forward through every transformation and split to the exact released containers and distribution population

Many-to-one and one-to-many transformations preserve contribution and destination. The scope can distinguish units exposed before and after an equipment intervention or artwork change.

05

Distribution records identify who received what

Customer, distributor, wholesaler, pharmacy, clinic, site, country, shipment, delivery, lot, serial, quantity, date, address, contact, onward distribution where available, and current inventory form the consignee map.

Returned, transferred, resold, administered, implanted, consumed, quarantined, destroyed, and unknown product states remain separate.

06

The recall strategy is an executable plan

Action type, depth, classification, urgency, channels, notification content, public warning, consignee obligations, response mechanism, return or correction instructions, effectiveness-check design, status-report frequency, authority contacts, and termination criteria are approved together.

Different markets and product types can use coordinated strategies without collapsing legal differences.

07

Communications come from controlled facts

Product identity, affected lots or serials, defect, hazard, actions, recognition instructions, return or correction process, contact, response deadline, and regulatory statements resolve from approved strategy data.

Letters, emails, portal notices, phone scripts, public warnings, and field instructions retain version, recipient population, approval, send event, delivery, and acknowledgment.

08

Every consignee becomes a tracked obligation

Contact attempt, channel, delivery, acknowledgment, response, inventory on hand, distributed onward, used, returned, corrected, destroyed, unavailable, questions, follow-up, and closure state remain visible.

Escalation rules prioritize nonresponders based on risk, quantity, depth, and time—not alphabetic order.

09

Effectiveness checks test whether the action worked

The plan defines level, sample population, selection method, attempt count, questions, evidence, acceptance, failures, escalation, and completion. Checks remain independent of routine response chasing where required.

Notification, acknowledgment, inventory response, return or correction, verification sample, exceptions, and completion form a measurable effectiveness system
Fig. 3 / Notification, acknowledgment, inventory response, return or correction, verification sample, exceptions, and completion form a measurable effectiveness system

A delivered email is not proof that affected product was identified and controlled.

10

Physical product is reconciled continuously

Manufactured, released, distributed, in company control, consignee stock, used, administered, implanted, returned, corrected, destroyed, recovered, exported, expired, sampled, and unaccounted quantities form a live balance.

Units and quantity bases remain explicit. Serialized and nonserialized populations can coexist without false precision.

11

Corrections and removals retain unit-level work

Field correction, relabeling, software update, inspection, repair, replacement, advisory notice, stock recovery, and destruction use controlled instructions and qualified personnel. Actual unit or lot state, work performed, evidence, verification, and restored status remain traceable.

Failed or incomplete correction returns to the action queue and may change the strategy.

12

Authority communication stays synchronized with operations

Initial notification, classification discussion, strategy, public communication, periodic status, reportable correction or removal, distribution updates, health-hazard evidence, effectiveness results, proposed termination, and final correspondence retain jurisdiction, version, submission, questions, commitments, and response.

Regulatory statements are generated from current governed facts while preserving each frozen submission.

One defect can create recalls in several markets, a device correction, a drug recall, a clinical-site notification, and a supplier containment. Shared root evidence and genealogy remain connected while each action retains its authority, scope, strategy, clocks, and termination.

Global coordination does not erase local accountability.

14

CAPA and supply decisions see the same population

Root cause, correction, preventive action, supplier response, process or design change, enhanced monitoring, effectiveness, shortage risk, replacement supply, and restart criteria connect to the recall and affected products.

The business can evaluate patient protection and supply continuity from the same controlled facts without weakening the quality decision.

15

Mock recalls test real retrieval and response

Scenario, trigger, target population, start time, participants, genealogy retrieval, distribution retrieval, contact data, quantity reconciliation, simulated communications, response, gaps, timing, and actions are recorded.

The exercise tests difficult branches and stale master data—not only the easiest recent batch. Actions remain linked to later evidence of effectiveness.

16

Status reporting is generated from live state

Scope, quantities, notifications, responses, nonresponders, returns, corrections, destruction, effectiveness checks, adverse outcomes, root cause, CAPA, and open issues aggregate without manual recounting.

Each report freezes the underlying state and calculation. Later corrections remain traceable.

17

Termination requires evidence, not calendar time

The decision considers reasonable communication attempts, action depth, response and recovery, correction completion, effectiveness, quantity reconciliation, product disposition, authority commitments, ongoing complaints, CAPA, and residual risk.

Closed recall does not mean erased recall. Surviving monitoring, complaints, records, and CAPA continue against the historical population.

18

Source systems retain commercial and regulatory specialization

ERP, WMS, serialization repositories, distributor systems, complaint platforms, and authority submission portals can remain authoritative for their native records. Seal does not invent distribution events that partners cannot provide.

It owns the governed case, population logic, cross-system genealogy, strategy, obligations, evidence completeness, reconciliation, effectiveness, and accountable decisions.

19

Where Seal is strongest

Seal is strongest when the recall cannot be managed as a mailing list. Because manufacturing genealogy, packaging, serials, inventory, distribution, complaints, quality events, CAPA, and communications are related, scope and progress remain explainable.

A CRM can send notices; an ERP can list shipments. Seal's advantage is proving that the right affected population was identified, reached, controlled, reconciled, and evaluated through termination.

20

Prove one difficult recall end to end

The first implementation should start from a supplier defect affecting part of several lots, trace through packaging and mixed distribution, approve a multi-market strategy, notify direct and indirect consignees, manage nonresponders, returns and corrections, sample effectiveness, reconcile quantities, report status, and reach termination.

Include incomplete genealogy, stale contact, onward distribution, one administered unit, a serial mismatch, damaged return, failed field correction, recall expansion, public warning, shortage assessment, and late complaint. The model is ready when every unknown remains explicit and actionable.

Operating model

Native control model
States and decisions owned by this blueprint
07 native controls
Health-Hazard Evaluation
Defect, exposure, severity, probability, vulnerable populations, clinical consequences, uncertainty, evidence, classification, and approval remain explicit.
Genealogy-Based Scope
Materials, equipment, bulk, lots, serials, packaging, markets, date ranges, shipments, and scope versions define the exact potentially affected population.
Recall Strategy & Authority
Action type, depth, urgency, channels, public warning, response, return or correction, reporting, commitments, and termination criteria stay controlled.
Consignee Notification
Approved content, recipient population, channels, sends, delivery, acknowledgment, onward distribution, questions, follow-up, and escalation remain trackable.
Effectiveness Checks
Risk-based samples, selection, independent contacts, attempts, questions, evidence, outcomes, failures, escalation, and completion prove the action worked.
Product Reconciliation
Produced, released, distributed, stocked, used, administered, implanted, returned, corrected, destroyed, recovered, and unknown quantities remain live.
Status & Termination Evidence
Frozen reports, authority questions, commitments, scope, progress, effectiveness, CAPA, residual risk, and termination decision remain inspection-ready.
Connected foundations
Existing blueprints supplying governed records and execution
06 foundations
RiskLife Sciences Quality Risk Management & ISO 14971 Software
Medical-device ISO 14971 risk files and pharmaceutical quality risk management with plans, hazard analyses, FMEAs, risk criteria, control options, verification, residual and overall risk, benefit-risk, production and post-production evidence, review, and change impact.
inventoryPharmaceutical Inventory & Material Lot Management Software
Material definitions, supplier and internal lots, containers, aliquots, labels, status, locations, quantities, expiry and retest, reservations, movements, usage, adjustments, storage excursions, reconciliation, traceability, and disposition.
RegRegulatory Change Impact & Commitment Management Software
Connect QMS changes, health-authority commitments, market assessments, submission dependencies, implementation controls, and closure evidence without turning the QMS into a second RIMS.
wmsPharmaceutical Warehouse Management System (WMS) Software
GMP receiving, quarantine, put-away, status and location control, sampling moves, FEFO allocation, picking, kitting, dispensing handoff, cold chain, cycle count, shipping, returns, and recall traceability.
AuditGxP Audit & Inspection Management Software
Plan risk-based internal, supplier and regulatory audit programs; qualify auditors; prepare scope and evidence; execute agendas, interviews and sampling; govern observations and findings; coordinate responses, CAPAs and commitments; verify effectiveness; trend themes; manage inspection rooms; and close with a complete record.
ARGxP Inspection Readiness & Regulatory Request Management Software
Inspection preparation, readiness assessments, front- and back-room request control, scoped evidence packages, point-in-time verification, secure review, response approval, commitments, observations, metrics, and continuous remediation across GxP systems.
Product Recall & Market Action Management Software owns the operating state above; connected foundations remain authoritative for their specialized records.

Capabilities

Defect, exposure, severity, probability, vulnerable populations, clinical consequences, uncertainty, evidence, classification, and approval remain explicit.
Materials, equipment, bulk, lots, serials, packaging, markets, date ranges, shipments, and scope versions define the exact potentially affected population.
Action type, depth, urgency, channels, public warning, response, return or correction, reporting, commitments, and termination criteria stay controlled.
Approved content, recipient population, channels, sends, delivery, acknowledgment, onward distribution, questions, follow-up, and escalation remain trackable.
05wmsconnected foundationReturns & Field Corrections
Unit or lot identity, custody, return, inspection, correction, repair, relabeling, replacement, verification, destruction, and restored state stay traceable.
Risk-based samples, selection, independent contacts, attempts, questions, evidence, outcomes, failures, escalation, and completion prove the action worked.
Produced, released, distributed, stocked, used, administered, implanted, returned, corrected, destroyed, recovered, and unknown quantities remain live.
Frozen reports, authority questions, commitments, scope, progress, effectiveness, CAPA, residual risk, and termination decision remain inspection-ready.

Entities

Entity
Description
Kind
WS
Market Action Signal
Complaint, deviation, OOS, safety, supplier, inspection, labeling, data, or authority trigger.
type
H
Health Hazard Evaluation
Defect, exposure, severity, probability, populations, consequences, uncertainty, and classification.
type
PS
Affected Population
Products, lots, serials, packs, markets, date ranges, genealogy basis, and scope history.
type
PS
Lot & Shipment Recall Scope
Genealogy filters, lots, packs, markets, shipments, consignee population, rationale, and versions.
template
PS
SCOPE-TX10 v03
Expanded population of 18,420 cartons across 142 direct consignees.
instance
F
Market Action
Recall, correction, removal, advisory, recovery, scope, strategy, authority, state, and termination.
type
F
Human Drug Voluntary Recall
Hazard evaluation, scope, strategy, authority, notifications, responses, returns, checks, and termination.
template
F
REC-TX10-2026-02
Class II voluntary recall of selected TX-10 lots for stopper-fragment risk.
instance
O
Consignee
Recipient, location, contact, shipments, onward distribution, affected quantity, and response state.
type
N
Recall Notification
Approved content, recipient, channel, version, send, delivery, acknowledgment, and follow-up.
type
N
Urgent Drug Recall Notice
Product recognition, defect, risk, lot list, immediate action, response, return, and contact.
template
N
NOTICE-TX10-US v02
Approved US notification issued after scope expansion.
instance
I
Consignee Response
Inventory, onward distribution, used, returned, corrected, destroyed, unavailable, questions, and evidence.
type
C
Effectiveness Check
Population, sample, method, attempts, questions, evidence, outcome, failure, and escalation.
type
C
Level B Effectiveness Check
Risk-based sample, independent contact, questions, evidence, acceptance, failure, and escalation.
template
C
EFF-TX10-WAVE-02
Second-wave check with 48 of 50 successful contacts and two escalations.
instance
C
Product Reconciliation
Produced, distributed, controlled, used, returned, corrected, destroyed, and unknown quantity states.
type
C
Recall Quantity Reconciliation
Distributed, used, stock, returned, corrected, destroyed, unavailable, unknown, and verified quantities.
template
C
RECON-TX10-2026-02
Live balance retaining 71 unaccounted cartons and documented follow-up.
instance
D
Authority Status Report
Frozen scope, contacts, responses, product, effectiveness, issues, CAPA, commitments, and submission.
type

FAQ

It manages the evidence and actions from an initiating quality or safety signal through hazard evaluation, scope, strategy, authority communication, consignee notification, responses, recovery or correction, effectiveness, reconciliation, and termination.
Yes. Common population, communication, response, effectiveness, reconciliation, and decision controls can be configured with product- and jurisdiction-specific recall, correction, removal, and reporting requirements.
Manufacturing genealogy, materials, equipment, lots, serials, packaging, date windows, markets, inventory, shipments, and onward distribution create a versioned scope with evidence for every change.
Yes, where distribution information is available. Direct recipients report onward distribution, and each downstream consignee becomes a tracked notification, response, quantity, and follow-up obligation.
They are a defined, risk-based verification that recipients received, understood, and appropriately acted on the recall or correction, using a controlled sample, questions, evidence, outcomes, and escalation.
Returned identity, quantity, custody, receipt, inspection, correction or destruction, and final disposition join the live balance of distributed, used, controlled, unavailable, and unknown product.
Yes. Approved instructions, qualified personnel, exact units, work performed, software or label version, parts, evidence, verification, restored status, failures, and reporting remain traceable.
Approved facts generate recipient-specific letters, email, portal notices, scripts, or public warnings. Every version, send, delivery, acknowledgment, response, and follow-up remains recorded.
No. Those systems can remain authoritative for shipments, inventory, and serial events. Seal connects their records to quality scope, strategy, obligations, effectiveness, reconciliation, and decisions.
Yes. Scenarios test genealogy and distribution retrieval, contacts, quantity balance, simulated communication and responses, timing, gaps, actions, and later effectiveness without contacting real consignees.
Evidence should support reasonable communication, action depth, response, recovery or correction, effectiveness, quantity reconciliation, product disposition, authority commitments, CAPA, and acceptable residual risk.
Run one difficult multi-market scenario from supplier defect through partial-lot scope, indirect distribution, notices, nonresponders, returns, correction, checks, reconciliation, reporting, expansion, and termination.

Related blueprints

NitrosaminesPharmaceutical Nitrosamine Risk Assessment & Control Software

Molecular risk to formation pathway. Acceptable intake to batch result. Mitigation to market implementation.

Govern product and API nitrosamine risk assessments, amine and nitrosating-agent knowledge, formation pathways, acceptable-intake limits, confirmatory methods and testing, mitigation, stability, supplier dependencies, regulatory reporting, and lifecycle review.

ComplaintProduct Complaint Handling & Safety Intake Software

One intake. Every issue, clock, investigation, and patient-safety handoff accounted for.

Capture product complaints across channels, preserve awareness, separate quality and safety assessments, investigate with lot and return evidence, report under governed rules, trend signals, and close the customer loop.

ControlledControlled Substance Inventory & DEA Recordkeeping Software

Every gram authorized. Every movement balanced. Every discrepancy investigated.

Control DEA registrations, schedules and authority, receipts, vault inventory, manufacturing issues and yields, transfers, returns, waste, destruction, physical inventories, reconciliation, and loss reporting.

SupplierPharmaceutical Supplier Quality Management Software

Supplier to site. Site to material and service. Qualification, agreements, lots, changes, performance, SCARs, and current approval connected.

Manage supplier, manufacturer and site identities; risk and material or service scope; qualification plans, questionnaires and audits; quality agreements; approved-supplier states; incoming lot and CoA performance; deviations, complaints and SCARs; supplier changes; scorecards, monitoring, requalification, restrictions, and disqualification.

CTSClinical Supply Management Software

Clinical supply. Blinded, available, accountable.

Protocol demand, kit and label design, packaging, randomization identifiers, depot and site inventory, temperature, returns, and reconciliation.

Cold ChainPharmaceutical Cold Chain & Temperature Excursion Management Software

Cold chain. Every handoff, temperature, exposed unit, and disposition in one record.

Qualify routes and shipping systems, assemble logger evidence, calculate exact exposure, identify the affected physical population, and make stability-backed disposition decisions without reconstructing a journey from emails.

Go live in 48 hours.